| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.67% | 58.18% | 58.86% | 53.66% | 56.90% | 56.85% | 55.37% | 52.31% | 46.72% | 46.32% | 44.84% | 45.41% |
| Operating Margin | -56.13% | -6.60% | 1.69% | -6.12% | 1.74% | 0.22% | 0.32% | 0.81% | -0.10% | -2.87% | -1.58% | 6.09% |
| EBITDA Margin | -54.12% | -4.76% | 3.00% | -4.84% | 3.24% | 2.10% | 2.03% | 2.82% | 1.19% | -1.40% | 0.03% | 7.24% |
| Net Margin | -65.51% | -13.18% | -3.04% | -8.40% | -0.24% | -7.65% | -4.03% | -2.42% | -0.85% | -4.12% | -17.52% | 2.17% |
| Current Ratio | 2.20 | 0.82 | 1.85 | 2.20 | 2.43 | 2.46 | 2.12 | 2.69 | 3.39 | 3.11 | 2.60 | 3.15 |
| Quick Ratio | 1.25 | 0.40 | 0.92 | 1.06 | 1.34 | 1.40 | 1.24 | 1.52 | 1.86 | 1.75 | 1.45 | 2.02 |
| Debt / Equity | 2.61 | 0.59 | 0.50 | 0.65 | 0.58 | 0.63 | 0.61 | 0.74 | 0.11 | 0.16 | 0.21 | 0.17 |
| ROE | -412.84% | -19.58% | -4.67% | -13.18% | -0.35% | -10.19% | -5.74% | -3.53% | -1.07% | -5.97% | -24.54% | 2.47% |
| ROA | -70.81% | -9.80% | -2.49% | -6.55% | -0.18% | -5.00% | -2.84% | -1.73% | -0.79% | -4.00% | -15.84% | 1.73% |
| Asset Turnover | 1.08 | 0.74 | 0.82 | 0.78 | 0.73 | 0.65 | 0.70 | 0.72 | 0.93 | 0.97 | 0.90 | 0.80 |
| Book Value / Share | 0.31 | 1.45 | 1.72 | 1.74 | 2.07 | 1.98 | 2.16 | 2.27 | 2.33 | 2.11 | 2.31 | 2.87 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, pre-clinical testing, drug development, bio-production, and therapy discovery in the life sciences sector. Its offerings include life science research instruments and consumables utilized by academic institutions, biopharmaceutical companies, biotechnology firms, government laboratories, universities, hospitals, and contract research organizations worldwide. The company markets its products under brands such as Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems, and Panlab through catalogs, websites, distributors, and direct sales forces. Harvard Bioscience, Inc. operates across geographical segments including the United States, Germany, United Kingdom, and rest of the world, with significant presence in North America, Europe, and Asia-Pacific. It maintains manufacturing and R&D facilities in the United States and Europe. Founded in 1901 and headquartered in Holliston, Massachusetts, Harvard Bioscience, Inc. plays a key role in supporting the global life science research ecosystem.